Liquidia Announces Poster Presentations at the Pulmonary Hypertension Professional Association (PHPN) Symposium

Core Insights - Liquidia Corporation will present four posters at the Pulmonary Hypertension Professional Association (PHPN) Symposium from September 18 to 20, 2025, in Seattle, focusing on innovative therapies for rare cardiopulmonary diseases [1][2]. Group 1: Presentation Details - The live thematic poster session will showcase new safety and exploratory efficacy data for LIQ861 (YUTREPIA™) in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) from the ASCENT study [2]. - Three previously published posters will also be presented, covering YUTREPIA's effects on cardiac effort, quality of life, and patient device usage [2][4]. Group 2: Poster Abstracts - The first poster will discuss initial safety and exploratory efficacy data on LIQ861 in PH-ILD patients [4]. - The second poster will provide insights into changes in cardiac effort in PH-ILD patients from the ASCENT trial [4]. - The third poster will focus on quality of life in pulmonary arterial hypertension (PAH) patients receiving LIQ861 in the INSPIRE study [4]. - The fourth poster will address the robustness of LIQ861 in patient misuse scenarios [5]. Group 3: Product Information - YUTREPIA is an inhaled dry-powder formulation of treprostinil, designed for the treatment of PAH and PH-ILD, aimed at improving exercise ability [5]. - The product utilizes Liquidia's PRINT technology, which allows for precise and uniform drug particle development for enhanced lung deposition [5][6]. - Liquidia is also developing L606, a sustained-release formulation of treprostinil, and markets generic Treprostinil Injection for PAH treatment [6].